Research Center of Health Management, Guangxi Zhuang Autonomous Region People's Hospital and Guangxi Academy of Medical Sciences, Nanning, China.
Department of Clinical Hematology, College of Pharmacy, Third Military Medical University, Chongqing, China.
Eur J Clin Invest. 2023 Dec;53(12):e14078. doi: 10.1111/eci.14078. Epub 2023 Aug 18.
There are contradictory effects regarding the effect of NAD+ precursor on blood pressure and inflammation. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of NAD+ precursor supplementation on blood pressure, C-reactive protein (CRP) and carotid intima-media thickness (CIMT).
PubMed/MEDLINE, Web of Science, SCOPUS and Embase databases were searched using standard keywords to identify all controlled trials investigating the effects of NAD+ precursor on blood pressure, CRP and CIMT. Pooled weighted mean difference (WMD) and 95% confidence intervals (95% CI) were achieved by random-effects model analysis for the best estimation of outcomes.
Twenty-nine articles (with 8664 participants) were included in this article. Results from meta-analyses of RCTs from random-effects models indicated a significant reduction in systolic (SBP) (weighted mean difference (WMD): -2.54 mmHg, p < .001) and diastolic blood pressure (DBP) (WMD: -2.15 mmHg, p < .001), as well as in CRP (WMD: -.93 mg/L, 95% CI -1.47 to -.40, p < .001) concentrations and CIMT (WMD: -.01 mm, 95% CI -.02 to -.00, p = .005) with the NAD+ precursors supplementation compared with the control group. In addition, a greater effect of supplementation with NAD+ precursors in reducing blood pressure (BP) were observed with the highest dose (≥2 g) and duration of the intervention (>12 weeks), as well as with NA supplementation when compared to NE.
Overall, these findings suggest that NAD+ precursor supplementation might have a beneficial effect on cardiovascular risk factors such as BP, CRP concentration and CIMT.
关于 NAD+前体对血压和炎症的影响,存在相互矛盾的结果。为了从这些结果中获得更好的观点,本研究旨在全面研究 NAD+前体补充对血压、C 反应蛋白(CRP)和颈动脉内膜中层厚度(CIMT)的影响。
使用标准关键字搜索 PubMed/MEDLINE、Web of Science、SCOPUS 和 Embase 数据库,以确定所有研究 NAD+前体对血压、CRP 和 CIMT 影响的对照试验。使用随机效应模型分析获得汇总加权均数差(WMD)和 95%置信区间(95%CI),以最佳估计结果。
本文纳入了 29 篇文章(8664 名参与者)。来自随机效应模型的 RCT 荟萃分析结果表明,收缩压(SBP)(WMD:-2.54mmHg,p<.001)和舒张压(DBP)(WMD:-2.15mmHg,p<.001)显著降低,以及 CRP(WMD:-.93mg/L,95%CI -1.47 至 -.40,p<.001)浓度和 CIMT(WMD:-.01mm,95%CI -.02 至 -.00,p=.005)与对照组相比,NAD+前体补充后浓度降低。此外,与对照组相比,补充 NAD+前体在降低血压(BP)方面的效果更大,这与补充 NAD+前体的剂量(≥2g)和干预持续时间(>12 周)较高以及补充 NA 而不是 NE 有关。
总体而言,这些发现表明,NAD+前体补充可能对血压、CRP 浓度和 CIMT 等心血管危险因素有有益影响。